The Global Antibiotic Research and Development Partnership’s (GARDP) lifesaving work is possible through smart, effective partnerships. GARDP brings together governments, the pharmaceutical and biotech industry, academia, civil society and people affected by diseases to develop treatments for drug-resistant infections, and to ensure they are available for every person who needs them. Partnerships are at the heart of our success in developing new and improved treatments. GARDP is currently working with more than 60 partners in 22 countries.

“Tackling the threat of drug resistant infections requires an urgent and truly global response. Critical to achieving this is GARDP’s public-private partnership approach and commitment to ensuring new and improved antibiotics are available for every person who needs them, wherever they live.”

– Glenda Gray, President & CEO, South African Medical Research Council

5 BY 25

GARDP is calling on the world to support the delivery of five new treatments by 2025 to tackle the drug-resistant infections that pose the greatest threat to global health and economic security. GARDP is seeking €500 million to develop these treatments. By acting now, collectively and with urgency, we can prevent a post-antibiotic era

Learn more >

GARDP is extremely grateful for the commitment of all its funders in helping us address the silent pandemic of antibiotic resistance.
Thank you for your loyal support.


Funding partnerships


  • Australian Department of Health
  • Canton of Geneva
  • Federal Ministry of Education and Research, Germany
  • Federal Ministry of Health, Germany
  • Ministry of Health, Luxembourg
  • Development Cooperation and Humanitarian Aid, Luxembourg
  • The Principality of Monaco
  • Ministry of Health, Labour and Welfare, Japan
  • Ministry of Health, Welfare and Sport, The Netherlands
  • South African Medical Research Council
  • Federal Office of Public Health, Switzerland
  • The Global AMR Innovation Fund, UK
  • National Institute for Health Research, UK
  • Department for International Development, UK
  • The Bill & Melinda Gates Foundation
  • Leo Model Foundation
  • Médecins Sans Frontières
  • Wellcome Trust

Research & development partnerships


  • Australian Research Council (ARC) Research Hub to Combat Antimicrobial Resistance​
  • University of Queensland’s Community for Open Antimicrobial Drug Discovery (CO-ADD)​
  • Kirby Institute​
  • Melbourne Sexual Health Clinic
  • University of Antwerp
  • REPAIR Impact Fund
  • Evotec​
  • InfectoPharm​
  • Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
  • All India Institute of Medical Sciences (AIIMS)
  • Indian Council of Medical Research
  • Dr Reddy’s​
  • Bugworks Research Inc.
  • Penta Foundation
  • Eisai
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo​
  • Shionogi
  • Kenyan Medical Research Institute (KEMRI)
  • Institut Pasteur Korea
The Netherlands
  • Department of Infectious Diseases, Public Health Service Amsterdam
South Africa
  • National Institute for Communicable Diseases (NICD)
  • South African Medical Research Council (SAMRC)
  • Stellenbosch University
  • University of KwaZulu Natal
  • Wits Health Consortium (WHC)
  • Wits Reproductive Health and HIV (Wits RHI), University of Witwatersrand
  • WHO Collaborating Centre for Gonorrhoea and other sexually transmitted infections,
    University Hospital, Örebro (WHOCC)
  • Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)
  • European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
  • Foundation for Innovative New Diagnostics (FIND)
  • Sandoz, the Novartis generics division
  • Drugs for Neglected Diseases initiative (DNDi)​
  • Bioversys AG
  • Bureau of AIDS, TB, and STIs, Department of Disease Control, Ministry of Public Health
  • Thailand US CDC Collaboration
  • Thai Red Cross, AIDS Research Center
  • University of Mahidol, Tropical Medicine Hospital
United Kingdom
  • British Society of Antimicrobial Chemotherapy (BSAC)
  • St George’s, University of London
  • Medical Research Council – Clinical Trials Unit (MRC CTU) at University College – London (UCL)
  • The University of Liverpool
  • The Wellcome Trust
  • Institute of Child Health, University College, London​
  • Oxford University
United States
  • American Society of Microbiology (ASM)
  • CARB-X, Combating Antibiotic Resistant Bacteria, led by Boston University
  • Clinton Health Access Initiative
  • Entasis Therapeutics
  • National Institutes of Health (NIH)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • The Pew Charitable Trusts
  • University of Alabama
  • University of Florida
  • Venatorx Pharmaceuticals

GARDP is also collaborating with research centres on activities in the following countries:

Bangladesh, Brazil, China, Greece, India, Italy, Kenya, the Netherlands, South Africa, Thailand, Vietnam, Uganda and the United States.



Learn about becoming a GARDP partner.

Become a partner